Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema

Subcutaneous C1‐inhibitor (HAEGARDA, CSL Behring), is a US Food and Drug Administration (FDA)‐approved, highly concentrated formulation of a plasma‐derived C1‐esterase inhibitor (C1‐INH), which, in the phase III Clinical Studies for Optimal Management in Preventing Angioedema with Low‐Volume Subcuta...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:CPT Pharmacometrics Syst Pharmacol
Main Authors: Zhang, Ying, Tortorici, Michael A., Pawaskar, Dipti, Pragst, Ingo, Machnig, Thomas, Hutmacher, Matthew, Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Longhurst, Hilary, Sidhu, Jagdev
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5869560/
https://ncbi.nlm.nih.gov/pubmed/29316335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12271
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker